Big Update Regarding Covid 19 Vaccine Covaxin, Check Here
Bharat Biotech reaffirmed the safety of its Covid-19 vaccine Covaxin, emphasizing its meticulous focus on safety during development. The company stated that Covaxin underwent extensive evaluation, involving over 27,000 subjects during licensure, and continued safety monitoring throughout its lifecycle. The vaccine’s safety record was highlighted, with no reported incidents of serious side effects like blood clots or myocarditis.
The vaccine’s approval under restricted use in clinical trial mode allowed for detailed safety reporting, involving hundreds of thousands of subjects. Additionally, the Union Ministry of Health evaluated Covaxin’s safety. Bharat Biotech stressed its commitment to safety, acknowledging that while vaccine efficacy might diminish over time, the impact on patient safety could endure.
As part of India’s Covid-19 immunization program, Covaxin conducted efficacy trials domestically, distinguishing it from other vaccines. Bharat Biotech underscored its role as an experienced innovator, prioritizing safety across all its vaccine development endeavors. This assurance from Bharat Biotech follows AstraZeneca’s recent acknowledgment of rare complications associated with its vaccine, sold in India as Covishield.
AstraZeneca’s admission in court regarding the potential for thrombosis with thrombocytopenia syndrome (TTS) prompted heightened scrutiny of vaccine safety.
Covaxin’s safety track record stands in contrast, with no such incidents reported. Bharat Biotech’s comprehensive approach to safety underscores its commitment to ensuring the well-being of vaccine recipients, aligning with global efforts to mitigate risks associated with Covid-19 vaccination.
